Academic Journal
Q1European Neuropsychopharmacology
About European Neuropsychopharmacology
European Neuropsychopharmacology is a scholarly journal published by Elsevier B.V.. SCImago 2025 places it in Q1 with an SJR of 2.334 and an H-index of 139.
Its listed coverage is 1990-2026 and its research categories include Biological Psychiatry (Q1); Neurology (Q1); Neurology (clinical) (Q1); Pharmacology (Q1); Pharmacology (medical) (Q1); Psychiatry and Mental Health (Q1). The 2025 dataset reports 152 documents and 2084 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Schizophrenia research and treatment, Treatment of Major Depression, Bipolar Disorder and Treatment, Tryptophan and brain disorders, Neurotransmitter Receptor Influence on Behavior, Neuroscience and Neuropharmacology Research.
Recent Research Articles
Latest publications matched automatically by ISSN.
Clinical guidance on the use of esketamine nasal spray for patients with treatment resistant depression: A European Delphi consensus report
Allan H. Young, Bernhard T. Baune, Beatrice Benatti, Djamila Bennabi et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.112907Prevalence and correlates of problematic social media use in Chinese adolescent psychiatric patients in Hong Kong
Paul Kin Shing Sze, Joyce Xu Hao Jin, Michelle Sze Yiu Yu, Ting Kin Ng et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113865Psychedelics and suicidality: A double-edged sword - risks, mechanisms, and moving forward
Maia Mallevays, Lucie Berkovitch
2026-12 · DOI: 10.1016/j.euroneuro.2026.113878Erratum to “Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study” [European Neuropsychopharmacology 107 (2026) 112801]
A Reif, Yağcıoğlu AE Anıl, I Bitter, J Buyze et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113860EEG resting-state gamma power as a potential biomarker of excitation / inhibition imbalance in autism: Evidence from the Autism Biomarkers Consortium for Clinical Trials
Vardan Arutiunian, Catherine A. Sugar, Adam Naples, Megha Santhosh et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113864The slow disappearance of the readable paper
Maria Sagué-Vilavella
2026-12 · DOI: 10.1016/j.euroneuro.2026.113863Long-term outcomes of childhood ADHD stimulant use trajectories
Noa E. van der Plas, Siri D.S. Noordermeer, Catharina A. Hartman, Pieter J. Hoekstra et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113861Genetic architecture of externalizing and internalizing traits in the general population and its link to psychiatric conditions and well-being: a multivariate approach
Barbara Šakić, Marieke Klein, Nina Roth Mota, Vera Goossens et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113546Social cognitive impairment across the bipolar disorder continuum: A comparative study of high-risk, first-episode, and chronic groups
Ezgi Cesim, Yaren Ecesu Turan, Özge İlhan, Muhammed Demir et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113862The average patient does not exist: Antidepressant evidence and the individual case
Stefan Jerotic, Anna Julia Krupa
2026-12 · DOI: 10.1016/j.euroneuro.2026.113868Viewing reproductive psychiatry through a three-patient framework
Zeljka Korade, Karoly Mirnics
2026-12 · DOI: 10.1016/j.euroneuro.2026.113866Cognitive reserve beyond ageing and dementia: A framework for early psychosis prevention and intervention
Rosa Ayesa-Arriola, Elena de la Serna, Inmaculada Baeza, Israel Contador et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.112919Global patterns of clozapine prescribing: An international comparison of prescribing indications across 15 regions
Ita Fitzgerald, Sarah O’Dwyer, Ciara Ní Dhubhlaing, Siobhan Gee et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.113547Corrigendum to “T70. Genetics of treatment resistant depression in Pakistan; update from the DIVERGE study” [European Neuropsychopharmacology 87, Supplement 1 (2024) 191]
Muhammad Umar, Arsalan Hassan, Fahad Hussain, Bakht Khizar et al.
2026-12 · DOI: 10.1016/j.euroneuro.2026.112918Functioning assessment short test for autism (FAST-A): a tool to evaluate adaptive functioning in autistic adults
Maria Martinez-Ramirez, Laura Gisbert Gustemps, Imanol Setién Ramos, Caterina del Mar Bonnín et al.
2026-11 · DOI: 10.1016/j.euroneuro.2026.112887Commentary on: The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD
Cleo L. Crunelle, Michiel W. Van Kernebeek, Mathias Luderer
2026-11 · DOI: 10.1016/j.euroneuro.2026.112908The impact of anhedonia on physical health and somatic diseases: an exploratory literature review
Koen Demyttenaere, Mohammed Alassiry, Anna Bobrowska, Andrea Fagiolini et al.
2026-11 · DOI: 10.1016/j.euroneuro.2026.112902Childhood maltreatment is linked to transdiagnostic age- and sex-specific cortical thinning and reduced amygdalar volume in young adults
Fabian Huth, Clara Vetter, Clara Weyer, Kyra Bröckel-Bundt et al.
2026-11 · DOI: 10.1016/j.euroneuro.2026.112900Dot the i’s and cross the t’s: Can we get resilience in bipolar disorder right, please?
Derek Clougher, Carla Torrent
2026-11 · DOI: 10.1016/j.euroneuro.2026.112884Emerging pharmacological and neuromodulation interventions for suicidal ideation and behaviour
Mauro Scala, Enrico Magrini, Ivana Leccisotti, Alessandro Serretti et al.
2026-11 · DOI: 10.1016/j.euroneuro.2026.112888Reviews
Community Reviews
Version History
September 8, 2026 at 12:03 am
September 8, 2026